Evidence map›Paper›PMID 28654200›Full record

ArticleChemMedChem2017

Preparation and Evaluation of Potent Pentafluorosulfanyl-Substituted Anti-Tuberculosis Compounds.

Garrett C Moraski, Ryan Bristol, Natalie Seeger, Helena I Boshoff, Patricia Siu-Yee Tsang, Marvin J Miller

Abstract read
In one paragraph

Article in ChemMedChem, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Imidazo[1,2‑ACS omega · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Antimicrobial agents and chemotherapy · 2021
    Article
  7. Article
  8. Amine-borane complex-initiated SFBeilstein journal of organic chemistry · 2020
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Garrett C MoraskiDepartment of Chemistry and Biochemistry, 103 Chemistry and Biochemistry, Montana State University, Bozeman, MT, 59717, USA.ORCID 0000-0002-6992-5584
Ryan BristolDepartment of Chemistry and Biochemistry, 103 Chemistry and Biochemistry, Montana State University, Bozeman, MT, 59717, USA.
Natalie SeegerDepartment of Chemistry and Biochemistry, 103 Chemistry and Biochemistry, Montana State University, Bozeman, MT, 59717, USA.
Helena I BoshoffTuberculosis Research Section, Laboratory of Clinical Infectious Diseases (LCID), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), 33 North Drive, Bethesda, MD, 20892, USA.
Patricia Siu-Yee TsangTuberculosis Research Section, Laboratory of Clinical Infectious Diseases (LCID), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), 33 North Drive, Bethesda, MD, 20892, USA.
Marvin J MillerDepartment of Chemistry and Biochemistry, University of Notre Dame, 347 Nieuwland Hall of Science, Notre Dame, IN, 46556, USA.ORCID 0000-0002-3704-8214
Montana State University · USNational Institutes of Health · USUniversity of Notre Dame · US

Funding

Development Of New Chemotherapeutics For TuberculosisZIAAI000693 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BARRY, CLIFTON · 2009 to 2025
$20.1M
Design, Syntheses and Studies of Novel Antituberculosis AgentsR37AI054193 · NIAID · UNIVERSITY OF NOTRE DAME · PI MILLER, MARVIN J · 2016 to 2025
$5.2M
Design/Syntheses/Studies/Novel Antituberculosis AgentsR01AI054193 · NIAID · UNIVERSITY OF NOTRE DAME · PI MILLER, MARVIN J · 2004 to 2014
$3.2M
NIAID NIH HHS HHSN272201100009CNIAID NIH HHS HHSN272201100009INIAID NIH HHS R01 AI054193NIAID NIH HHS R37 AI054193
6 · The paper itself

Abstract

The global fight to stop tuberculosis (TB) remains a great challenge, particularly with the increase in drug-resistant strains and a lack of funding to support the development of new treatments. To bolster a precarious drug pipeline, we prepared a focused panel of eight pentafluorosulfanyl (SF

Indexed as

AnimalsAntitubercular AgentsCell LineDrug Resistance, BacterialHumansImidazolesMicrobial Sensitivity TestsMycobacterium tuberculosisPyridinesStructure-Activity RelationshipSulfanilic AcidsAntitubercular AgentsImidazolesPyridinesSulfanilic Acidsdrug resistanceimidazo[1,2-a]pyridinesimidazo[2,1-b]thiazolesMycobacterium tuberculosispentafluorosulfanyl

Identifiers

PMID28654200
PMCPMC5603227
OpenAlexW2729029554

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.